Physician profile
Gloria E Chaney
NPI 1548252240
$2,096.58
in general payments reported to CMS, 2019-2025
20 companies · $705 in 2025
The $705 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $108 · 2021: $12.20 · 2022: $42.08 · 2023: $350 · 2024: $428 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.90 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $394.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $198.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $152.15 | 2019-2025 | Verquvo, Capvaxive, Vaxneuvance |
| Abbvie INC. | $100.63 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $98.62 | 2023-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $67.23 | 2019 | |
| Mylan Specialty L.P. | $64.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.68 | 2023-2025 | |
| Lilly USA, LLC | $46.18 | 2024-2025 | Jardiance, Mounjaro |
| Dexcom, INC. | $45.08 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $37.50 | 2025 | |
| Exact Sciences Corporation | $29.66 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $27.94 | 2019 | |
| Allergan, INC. | $27.13 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $24.50 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2019 | |
| Amarin Pharma, INC. | $14.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Chaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.